Continued Improvement of Investigator and Patient Reported Outcomes into the 52-Week Maintenance Period were Observed with Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis (SEASIDE CHINA)

rademikibart (CBP-201) - Suzhou Connect Biopharma

Jonathan I. Silverberg* 1; Jianzhong Zhang 2; Jiawang Guo 3; Jili Yun 3; Wubin Pan 3; Zheng Wei 4; Raul Collazo 4

Aug 6, 2024